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Temozolomide(TMZ)hasbecomeakeytherapeuticagentinpatientswithmalignantgliomas;however,itssurvivalbeneﬁtremains
unsatisfactory. Valproic acid (VPA) has emerged as an anticancer drug via inhibition of histone deacetylases (HDACs), but the
therapeutic advantages of a combination with VPA and TMZ remain poorly understood. The main aim of the present study was to
determine whether an antitumor eﬀect could be potentiated by a combination of VPA and TMZ, especially in TMZ-resistant cell
lines.AcombinationofVPAandTMZhadasigniﬁcantlyenhancedantitumoreﬀectinTMZ-resistantmalignantgliomacells(T98
and U138). This enhanced antitumor eﬀect correlated with VPA-mediated reduced O6-methylguanine-DNA methyltransferase
(MGMT) expression, which plays an important role in cellular resistance to alkylating agents. In vitro, the combination of these
drugs enhanced the apoptotic and autophagic cell death, as well as suppressed the migratory activities in TMZ-resistant cell lines.
Furthermore, in vivo eﬃcacy experiment showed that treatment of combination of VPA and TMZ signiﬁcantly inhibited tumor
growth compared with the monotherapy groups of mice. These results suggest that the clinical eﬃcacy of TMZ chemotherapy in
TMZ-resistant malignant glioma may be improved by combination with VPA.
1.Introduction
Malignant gliomas are the most common primary tumors of
the central nervous system. Although multimodality treat-
ments exist, including extensive tumor resection, radiation
therapy,andchemotherapy,theirprognosisispoor.Recently,
thealkylatingagenttemozolomide(3,4-dihydro-3-methyl-4-
oxoimidazo-[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, TMZ)
has received much attention as a treatment for malignant
gliomas [1]. A trial of concomitant and adjuvant TMZ
in addition to radiotherapy for new glioblastomas demon-
strated an increase in median survival from 12.1 to 14.6
months and an increase in the 2-year survival rate from 10 to
26% compared with radiotherapy alone [2]. However, recent
studieshaveindicated thattheresistancetoTMZobserved in
malignant gliomas is related to the DNA repair enzyme, O6-
methylguanine-DNAmethyltransferase(MGMT),leadingto
the replication of DNA and the growth of tumors [3–6].
Valproic acid (VPA) is an approved drug for the treat-
ment of epileptic seizures, bipolar disorders, and migraine
and acts via inhibition of the transamination of gamma-
aminobutyric acid. VPA is a short-chain fatty acid that
inhibits histone deacetylases (HDACs) [7–9]. HDACs play
an important role in chromatin remodeling and gene
expression via posttranslational modiﬁcation of chromatin-
associated histones. HDAC inhibition induces tumor cell
diﬀerentiation, apoptosis, and growth arrest [10, 11]. VPA
has been examined as an HDAC inhibitor (HDACI) in2 Journal of Biomedicine and Biotechnology
numerous preclinical and clinical trials for solid tumors and
leukemias [12, 13].
Recent investigation shows that VPA enhanced the
apoptotic cell death by TMZ in human glioma cell lines
[14]. However, antitumor eﬀects of VPA in TMZ-resistant
glioma cells remain poorly documented. In this study, we
investigated the ability of VPA to increase the sensitivity of
four human malignant glioma cell lines (U87, U138, T98,
and U251) to the cytotoxic eﬀects of TMZ in vitro. We also
examined whether VPA regulates the expression of MGMT
and enhances cytotoxicity in TMZ-resistant glioma cells.
2.MaterialsandMethods
2.1. Cell Culture and Reagents. U87, U138, T98, and U251
cells were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). U87 and T98
cells were grown in Eagle’s Minimum Essential Medium
(Invitrogen, Grand Island, NY), and U138 and U251 cells
w e r eg r o w ni nD u l b e c c o ’ sm o d i ﬁ e dE a g l e ’ sm e d i u m( I n v i t -
rogen). Both media were supplemented with 2mmol/L L-
glutamine, 100U/mL penicillin, 100μg/mL streptomycin,
and 10% fetal bovine serum (FBS), purchased from Invit-
rogen (Carlsbad, CA, USA). Cells were incubated at 37◦C
in a humidiﬁed atmosphere containing 5% CO2. Temozolo-
mide (3,4-dihydro-3-methyl-4-oxoimidazo-[5,1-d]-1,2,3,5-
tetrazine-8-carboxamide, TMZ), valproic acid (VPA), and
autophagy inhibitor 3-methyladenine (3-MA) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). The
caspase inhibitor Z-VAD-FMK was acquired from R&D
Systems (Minneapolis, MN, USA).
2.2. Growth Inhibitory Eﬀect of VPA or TMZ in Glioma Cells.
The inhibition of the growth of the four glioma cell lines by
VPA or TMZ was evaluated from the concentration required
for 50% growth inhibition (IC50) compared with untreated
controls. Cells were seeded into wells of a 96-well plate at
a density of 1 × 103 cells/well in medium containing 10%
FBS and were incubated for 72h. Subsequently, cells were
washed twice with the medium and incubated with fresh
medium (control), medium containing 0.5–16mM VPA,
or medium containing 0.5–1,000μM TMZ. After exposure
to the various concentrations of VPA or TMZ for 48h,
cells were detached by trypsinization and the viable cell
population was determined using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), as described
previously [15].
2.3. Western Blot Analysis. Antibodies were obtained from
commercial sources: anti-MGMT from Cell Signaling Tech-
nology (Danvers, MA, USA), anti-β-actin from Applied
Biological Materials (Richmond, BC, Canada), anti-LC3B
from Sigma, and anti-Bcl-2, anti-Bak, and anti-caspase-3
from New England Biolabs (Ipswich, MA, USA). For western
blot analysis, cells were rinsed with phosphate-buﬀered
saline (PBS) and lysed for 30 min on ice in RIPA-B buﬀer
(0.5% Nonidet P-40, 20mM Tris, pH 8.0, 50mM NaCl,
50mM NaF, 100μMN a 3VO4, 1mM dithiothreitol, and
50μg/mL of phenylmethanesulfonyl ﬂuoride). The insoluble
material was removed by centrifugation at 12,000 rpm for 20
min. The supernatant was resolved by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and
the resolved proteins were transferred to a nitrocellulose blot
membrane. The blots were blocked in PBS with 5% skim
milk and 0.05% Tween-20, incubated with the appropriate
antibodies, and subsequently incubated with secondary
antibodies conjugated with horseradish peroxidase. The
blots were assayed using an enhanced chemiluminescence
detection system (Amersham Biosciences, Piscataway, NJ,
USA).
2.4. Cell Migration Assay. The migratory ability of glioma
cells (T98 and U138) was determined using Transwell plates
(CorningCostar,Cambridge,MA,USA)thatwere6.5mmin
diameterwith8μmporeﬁlters.Inbrief,cellsweresuspended
in serum-free medium and seeded into the upper well, and
600μL of 20% FBS-containing medium was placed in the
lower well of a Transwell plate. Following incubation for 5h
at 37◦C, cells that had not migrated from the upper side
of the ﬁlter were scraped oﬀ with a cotton swab, and ﬁlters
were stained with the Diﬀ-Quik three-step stain set (Sysmex,
Kobe, Japan). The number of cells that had migrated to the
lower side of the ﬁlter was counted under a light microscope
at ×200 magniﬁcation in ﬁve randomly selected ﬁelds.
2.5. Animal Experiments. Two established human glioblas-
toma tumor cell lines (T98 and U138) were used in this
experiment. However, U138 cell line was not tumorigenic
when injected into BALB/c nude mice (female, 6 weeks old).
BALB/c nude mice bearing T98 tumors were randomized to
four groups (n = 5 in each group) and treated when the
subcutaneous tumors had reached a volume between 100
and 200mm3. VPA (300mg/kg) was administered i.p. 6h
before the i.p. injection of TMZ (50mg/kg). Control (PBS)
mice, or mice receiving VPA or TMZ alone, also received
the corresponding vehicle. Treatments were repeated at 24
h intervals for a total of ﬁve doses. Tumor length (a)
and width (b) were measured in situ at 4-day intervals
using digital calipers, and tumor volumes were calculated
according to the following formula: V(mm3) = a × b2/2.
The signiﬁcance of diﬀerences between control and treated
tumors was evaluated using ANOVA.
2.6. Statistical Analysis. All data are expressed as means
± SEMs. The signiﬁcance of diﬀerences between diﬀerent
test conditions was determined using one-way ANOVA and
Student’s t-test. Probability values <0.05 were considered
signiﬁcant.
3. Results
3.1. Antitumor Eﬀect of VPA and TMZ on Human Malignant
Glioma Cells. To determine the eﬀects of VPA or TMZ alone
in malignant glioma cells, we treated four malignant glioma
cell lines with 0–16mM VPA or 0–1,000μMT M Zf o r7 2h
and assessed the number of viable cells. VPA and TMZ hadJournal of Biomedicine and Biotechnology 3
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Figure 1: Sensitivity of four human glioma cell lines to TMZ and VPA. (a) The number of viable cells was counted at 72h after the addition
of VPA (0–16mM) to the culture medium. (b) The viability of glioma cells was also analyzed via MTT assay 72h after TMZ (0–1,000μM)
treatment. Points, mean; bars, SE. The results are representative of three independent experiments.
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Figure 2: Antitumor eﬀect of a combination of VPA with TMZ in glioma cell lines. Malignant glioma cell lines were treated with VPA
(4mM) or TMZ (50μM), alone or in combination, for 72h. (a) The combination of VPA with TMZ had combined antitumor eﬀects in U87
and U251 cells. (b) Signiﬁcant enhanced antitumor eﬀects were observed in T98 and U138 cells (TMZ-resistant glioma cell lines). Columns,
mean; bars, SE.
∗P < 0.05, ANOVA. The results are representative of three independent experiments.
a growth inhibitory eﬀect on all tumor cell lines in a dose-
dependent manner. The IC50 value of VPA for U87 and
U251 cells was 6mM, whereas the IC50 value of VPA for
T98 and U138 cells exceeded 8mM. In contrast, the IC50
of TMZ for U87 and U251 was <500μM, although T98 and
U 1 3 8c e l l sw e r er e s i s t a n tt oT M Z( I C 50 > 500μM; Figure 1).
Based on these results, a concentration of VPA of 4mM
and a concentration of TMZ of 50μM, which were lower
concentrations than the respective IC50 value, were chosen
for the following in vitro combination experiments.
3.2. Combined Eﬀect of VPA and TMZ in Human Malignant
Glioma Cells. To assess the eﬀect of the combination of
VPA and TMZ in the malignant glioma cell lines, cells were
incubated in culture medium containing 4mM VPA, 50μM
TMZ, or a combination of 4mM VPA and 50μMT M Z
for 72h. As shown in Figure 2(a), the combination of VPA
and TMZ had a combined antitumor eﬀect in U87 and
U251 cells. In addition, a signiﬁcant enhanced antitumor
eﬀect of the combined treatment of VPA and TMZ was also
observed in T98 (P = 0.034, combination treatment versus4 Journal of Biomedicine and Biotechnology
single treatment) and U138 cells (P = 0.042, combina-
tion treatment versus single treatment; Figure 2(b)). These
results suggest that the combination of VPA with TMZ has
combined or enhanced antitumor eﬀects in the malignant
glioma cell lines. Furthermore, this ﬁnding implies that the
cell growth inhibitory eﬀect of TMZ is enhanced by VPA in
TMZ-resistant cells.
3.3. Eﬀect of VPA on the Expression of MGMT in TMZ-
Resistant Glioma Cells. To examine the involvement of
MGMT in the malignant glioma cell lines, the expression
of the MGMT protein was analyzed by western blot. We
detected expression of MGMT in the TMZ-resistant cell
lines T98 and U138. In contrast, MGMT protein expression
was not detected in the TMZ-sensitive cell lines U87 and
U251 (Figure 3(a)). This result indicates that the sensitivity
of TMZ is correlated with the expression of the MGMT
protein, which is consistent with the results of a previous
study [3]. To determine the eﬀect of VPA on the expression
of MGMT in TMZ-resistant glioma cells (T98 and U138),
western blot analyses were performed after the application
of various concentrations of VPA (0–8mM). The expression
of MGMT in T98 and U138 cells was decreased by VPA in
a dose-dependent manner (Figure 3(b)). We also evaluated
the combination eﬀect under the concentrations of VPA (0–
8mM) and TMZ (50μM ) .Th ec ellvi a b i l i tyw a sd ec r e a s edb y
VPA in a dose-dependent manner (Figure 3(c)). Moreover,
cell death induced by combination can be signiﬁcantly
alleviated by caspase inhibitor Z-VAD-fmk (20μM) and
autophagy inhibitor 3-MA (2mM) (P<0.05, combination
treatment versus inhibitor treatment). Taken together, these
results suggest that VPA downregulates MGMT and is
associated closely with TMZ sensitivity in TMZ-resistant
glioma cells.
3.4. Eﬀects of Apoptotic and Autophagic Cell Death by VPA
and TMZ Combination in TMZ-Resistant Glioma Cells. To
identify the synergistic eﬀects of VPA on TMZ-induced
apoptosis, we performed western blot analyses using anti-
bodies against Bcl-2, Bak, and caspase-3 in T98 and U138
cells treated with 4mM VPA and/or 50μMT M Z .T h e
expression of the proapoptotic molecule Bak was increased
by VPA alone and, to a much greater extent, by the VPA and
TMZ combination. Cleaved caspase-3, which is a terminal
eﬀector of apoptosis, was also increased by VPA and also to
a much greater extent by the VPA and TMZ combination.
However, the expression of the antiapoptotic molecule Bcl-
2 was decreased by VPA alone and by the VPA and TMZ
combination. Similar patterns were observed for U138 cells
(Figure 4(a)).Inaddition,weexaminedtheexpressionoftwo
microtubule-associated protein light-chain-3 (LC3) forms,
LC3-I and LC3-II, using western blot analysis, since LC3-II
correlates with the extent of autophagosome formation [16].
Expression of LC3-II increased in TMZ-resistant glioma cells
treated with VPA and TMZ combination. These ﬁndings
suggest that the combination of VPA and TMZ enhances
TMZ-induced apoptotic and autophagic cell death in TMZ-
resistant glioma cells.
3.5. Suppression of TMZ-Resistant Glioma Cell Migration by
VPA and TMZ Combination. It has been reported that TMZ
modiﬁes caveolin-1 expression in vitro and in vivo in glioma
cells, a feature that directly aﬀects glioma cell migration
properties. TMZ decreases β1 integrin expression and mod-
ulatesCyr61signalingandactincytoskeletonpolymerization
in GBM cell lines [17]. We investigated the eﬀect of VPA
and TMZ on TMZ-resistant glioma cell migration using a
transwell migration assay. VPA and TMZ separately did not
aﬀect cell migration, but the combination of VPA and TMZ
was signiﬁcantly suppressed the migration of T98 cells (P =
0.021, combination treatment versus single treatment) and
U138 cells (P>0.05) (Figure 5). This result suggests that
VPA sensitizes the antimigratory activity of TMZ in TMZ-
resistant glioma cells.
3.6. Reduction of TMZ-Resistant Glioma Xenograft Growth
after Treatment with a Combination of VPA and TMZ. We
also investigated the synergistic eﬀects of a combination of
VPA and TMZ in a human glioma xenograft-nude mouse
model. TMZ (50mg/kg) alone did not decrease the growth
of the T98 tumor (P > 0.05). VPA (300mg/kg) alone
suppressedT98tumorgrowthslightly(P >0.05).Incontrast,
a combination of VPA and TMZ decreased T98 tumor
growth to a very signiﬁcant extent (P=0.003, combination
treatment versus single treatment). Therefore, the combi-
nation treatment decreased tumor growth signiﬁcantly in
the TMZ-resistant glioma xenografts compared with the
monotherapies (Figure 6).
4. Discussion
Despite the multimodality treatments available, including
surgery, radiation therapy, and chemotherapy, the prognosis
of malignant gliomas remains poor. TMZ is considered
as a standard chemotherapeutic regimen for the ﬁrst-
line treatment of malignant gliomas. However, TMZ does
not exhibit uniform sensitivity to malignant gliomas. The
resistance of some malignant gliomas to TMZ is related
to the DNA repair enzyme MGMT, via the removal of
the alkylating lesion at the O6 position of guanine. This
causes the replication of DNA and the growth of malignant
gliomas [3–6]. In the present study, we demonstrated that
malignant glioma cell lines exhibit diﬀerential expression of
the MGMT gene, which is in keeping with the results of
ap r e v i o u ss t u d y[ 18, 19]. MGMT expression is suppressed
at the level of transcription by CpG methylation within the
MGMT promoter, and almost half of primary GBM tumor
samples have evidence of promoter hypermethylation, as
determinedbymethylation-speciﬁcPCR(MS-PCR)[20,21].
Furthermore, tumor MGMT promoter hypermethylation
was associated with prolonged survival (46% 2-year sur-
vival) in GBM patients treated with TMZ and radiation
as compared to those patients without evidence of tumor
hypermethylation (14% 2-year survival) [22]. In this study,
the MGMT status, including promoter hypermethylation
(data not shown), quantitative mRNA expression (data
not shown), and protein expression in glioma cells, alsoJournal of Biomedicine and Biotechnology 5
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Figure 3: Eﬀect of VPA on the expression of MGMT in TMZ-resistant glioma cells. (a) Cell lysates of four human glioma cell lines were
subjected to western blotting using an anti-MGMT antibody. This revealed an absence of MGMT expression in the U87 and U251 cell lines.
In contrast, the other two cell lines, T98 and U138, exhibited MGMT expression at the protein level. (b) MGMT expression in the T98
and U138 TMZ-resistant cells treated with varying concentrations of VPA (0–8 mM). β-Actin was used as a loading control. (c) Cells were
exposed to medium containing various concentrations of VPA (0–4 mM) with 50μM TMZ for 72 h and were measured using MTT assay.
Columns, mean; bars, SE.
∗P < 0.05, Student’s t-test. The results are representative of three independent experiments.
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Figure 4: Induction of apoptotic and autophagic cell death in TMZ-resistant glioma cells by VPA and TMZ combination. T98 and U138
cells were untreated or treated with VPA, TMZ, or their combination. (a) The expression of MGMT, Bcl-2, Bak, and caspase-3 was evaluated
using western blotting. (b) Conversion of LC3-I to LC3-II was also determined by western blotting. β-actin was used as a loading control.
The results are representative of three independent experiments.6 Journal of Biomedicine and Biotechnology
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Figure 5:AntimigrationeﬀectofacombinationofVPAandTMZinTMZ-resistantgliomacells.Transwellmigrationassaydemonstratesthe
migration of TMZ-resistant glioma cells in response to 20% FBS. (a) Representative photomicrographs of stained ﬁlters showing migrating
T98 and U138 (data not shown). Magniﬁcation, ×100. (b) T98 and U138 cells were pretreated with VPA (4mM) or TMZ (50μM), alone or
in combination, for 72h. Serum-induced T98 cell migration was signiﬁcantly inhibited by VPA and TMZ combination. Serum-free medium
(SFM)was usedas aexperimental control. Columns,mean; bars,SE.
∗P < 0.05,ANOVA.Theresultsarerepresentative ofthreeindependent
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Figure 6: Inhibition of the growth of T98 xenografts treated
with VPA and TMZ. BALB/c nude mice bearing T98 cells were
distributed into four treatment groups: ﬁlled circle, PSB; open
circle, VPA (300mg/kg); ﬁlled triangle, TMZ (50mg/kg); open
triangle, VPA (300mg/kg) + TMZ (50mg/kg). Points, mean; bars,
SE.
∗∗P < 0.01, ANOVA. PBS was used as a control. The results are
representative of two independent experiments.
conﬁrmed that MGMT promoter methylation suppresses
gene transcription and reduces MGMT protein expression.
Therefore, suppression of MGMT expression mediated by
promoter hypermethylation may be an important factor
inﬂuencing TMZ sensitivity.
Recently,VPAhasemergedasananticancerdrugbecause
of its function as an inhibitor of HDACs. Several previous
reports indicate that VPA induces cancer cell apoptosis
and anticancer immunity. It also inhibits tumor-associated
inﬂammation and angiogenesis, invasion, and proliferation
of cancer cells [23, 24]. Here, VPA had an anticancer
eﬀect on human malignant glioma cell lines. However, the
sensitivity to VPA varied among glioma cell lines. VPA had
an anticancer eﬀect in U87 and U251 cells at low dosages
of the drug; however, T98 and U138 cells were similarly
aﬀected only at a high dosage of VPA (Figure 1). This
phenomenon may reﬂect a diﬀerence in HDAC-induced
histone hyperacetylation or posttranslational protein acety-
lation among the glioma cell lines. Numerous in vitro studies
use concentrations of VPA in a higher dosage range, mostly
f r o m1u pt o1 0m M[ 25–27]. Furthermore, the sensitivity to
VPA was diﬀerent among glioma cell lines. Therefore, a high
dosage of VPA (4 mM) was chosen for the following in vitro
combination experiments. However, further work needs to
bedoneinrelationtothesafetyandtoxicityofVPAandTMZ
at optimal therapeutic concentrations.
Several preclinical and clinical studies have proved
that hypomethylating drugs, such as 5-aza-2 -deoxycytidine
(5-aza-CdR; decitabine), and HDACI, such as valproic
acid (VPA; Depakine) and suberoylanilide hydroxamic acid
(SAHA; vorinostat), have potent anticancer activity and
promising therapeutic potential [13, 28–30]. Previous exper-
imental results indicate that the anticancereﬀectsof VPA can
be increased by its combination with other drugs [31, 32].
Among them, a limited number of studies addressed the
combination with VPA and other anticancer drugs for the
treatment of glioma. An in vitro study of the synergistic
eﬀect of VPA and etoposide on U87, U251, and LN18 cells
demonstrated that VPA sensitizes glioma cell lines to the
cytotoxic eﬀects of etoposide by inducing diﬀerentiation and
upregulating the expression of p21/WAF1 and both isoforms
of topoisomerase II [33]. Another study reported that the
synergistic eﬀect of the association of VPA with nitrosourea
(BCNU) on human glioma cell lines in vitro was related to
an increased blockage of the cell cycle with accumulation in
the S-G2/M phases, rather than an increase in programmed
cell death [34]. The present investigation of the eﬀect of
VPA/TMZ revealed that U87 and U251 cells were sensitive
to VPA or TMZ independently. Therefore, they did not show
anenhancedantitumor eﬀecton the combination treatment.
However, an enhanced antitumor eﬀe c tw a sf o u n di nT M Z -
resistant T98 and U138 cells (Figure 2). This phenomenon
can be explained by a VPA-mediated sensitization of T98
and U138 cells to TMZ. The evaluation of MGMT status
in T98 and U138 cells after VPA treatment demonstrated
that MGMT expression was decreased by VPA in a dose-
dependent manner. This result can be explained by the
HDACI function of VPA, which remodels chromatin [35].
Downregulation of the MGMT protein may not remove
alkylating lesions at the O6 position of guanine and increase
the sensitivity to TMZ in VPA-treated TMZ-resistant cells.
5. Conclusions
This study demonstrated that the combination treatment of
VPA/TMZ regulates TMZ sensitivity via the downregulation
of MGMT and has anticancer eﬀects in vitro/in vivo in TMZ-
resistant glioma cells. Although further studies are needed
to determine the exact mechanism underlying the inhibition
of MGMT expression, these results suggest that the clinical
therapeutic eﬃcacy of TMZ in malignant glioma can be
enhanced by combination with VPA.
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